Iambic Therapeutics, a clinical-stage biotech company harnessing its AI-driven discovery platform, has been named to the 2024 Endpoints News list of “Biotech’s Most Promising Startups.” This annual award highlights innovative life science companies working to develop breakthrough therapies.
“By integrating AI and machine learning with automated experimentation, Iambic has transformed the speed and accuracy of drug discovery. We successfully advanced our lead program from discovery to clinical trials in under 24 months, a significant improvement over traditional timelines,” said Tom Miller, PhD, CEO and co-founder of Iambic. “Being recognized by Endpoints reflects our team’s unwavering commitment to developing novel, potentially best-in-class treatments that address significant unmet needs in oncology and other areas.”
Iambic is building an internal pipeline of drug candidates identified through its platform, which combines AI models for protein structure prediction and holistic drug design with high-throughput chemistry and biology experimentation. The pipeline includes IAM1363, a selective small molecule inhibitor targeting both wild-type and oncogenic HER2 mutants currently in Phase 1/1b trials, as well as a potential first-in-class selective dual CDK2/4 inhibitor for various cancer indications, an allosteric KIF18A inhibitor, and additional programs.
Additionally, Iambic recently announced a strategic research partnership with Lundbeck to leverage its drug discovery platform for advancing research into neurological diseases, expanding its impact into new therapeutic areas.
About the Iambic Therapeutics AI-Driven Discovery Platform
Iambic’s AI-driven platform tackles complex drug design challenges, utilizing innovative technologies like the Iambic NeuralPLexer, which enhances structural predictions of protein-ligand complexes. By integrating physics principles into its AI architectures, the platform increases data efficiency and explores a wide range of chemical structures. Its algorithms facilitate the identification of new chemical mechanisms for targeting challenging biological entities, optimizing therapeutic profiles, and discovering candidates with unique properties. The close integration of AI-generated designs and automated experimental execution allows Iambic to conduct weekly design-make-test cycles.
About Iambic Therapeutics
Founded in 2019 and based in San Diego, California, Iambic Therapeutics is revolutionizing the drug discovery landscape with its innovative AI-driven platform. The company has assembled a premier team of AI specialists and seasoned drug developers, known for their success in delivering clinically validated therapeutics. Iambic’s platform is designed to rapidly produce high-quality, differentiated therapeutics across multiple target classes and mechanisms, advancing clinical assets to meet urgent patient needs.
